- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Roche, Chugai Pharma to transfer Bonviva business in Japan to Taisho Pharma
Tokyo: Chugai Pharmaceutical Co., Ltd., and Taisho Pharmaceutical Co., Ltd. have announced that Chugai, Taisho, and F. Hoffmann-La Roche Ltd (hereafter, Roche) have entered into an agreement to transfer the business in Japan concerning the ibandronate sodium hydrate injection [brand name: Bonviva Injection 1 mg Syringe] and the oral formulation [brand name: Bonviva Tablet 100 mg] (collectively "Bonviva"), from Roche and Chugai to Taisho. The closing of the transaction is expected to take place after certain conditions including approvals from relevant authorities are fulfilled. Chugai in-licensed Bonviva from Roche and is the marketing authorization holder in Japan.
Read also: Roche, Jnana Therapeutics collaborate for discovery of small molecule drugs for cancer
Chugai and Taisho concluded an agreement in 2006 to co-develop and co-market Bonviva in Japan. After conducting clinical studies in Japan, the two companies have been jointly marketing Bonviva since the launch of the injection in 2013. In consideration of the maturity of the product lifecycle, Chugai, Taisho, and Roche revisited the marketing of Bonviva in Japan and concluded that Taisho should solely market Bonviva after transferring assets related to Bonviva that are owned by Roche and Chugai, including the marketing authorization and intellectual property rights (patents and trademarks, etc.), to Taisho.
Following the signing of the asset purchase agreement, Taisho and Chugai will proceed with the necessary administrative and legal procedures for the completion of the transaction. The transfer of the marketing authorization is scheduled to take place on April 3, 2023. Taisho will be solely responsible for the marketing of and information provision activities for Bonviva in Japan thereafter.
Read also: Chugai Pharma Herceptin gets Japanese nod for additional indication of salivary gland cancer
Roche is a Swiss multinational healthcare company headquartered in Basel, Switzerland.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751